GSK heads down digital path creating specific role for incomer

pharmafile | July 27, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  GSK, biotech, drugs, pharma, pharmaceutical 

GSK has created a whole new role to push the company to strengthen its digital, data and analytics strategy, with Karenann Terrel unveiled as the new Chief Digital and Technology Officer.

It’s another interesting appointment from Walmsley, as she seems to have set her sights on recruiting individuals as a means of transforming the business.

The appointment of Luke Miels has been much talked about, but there have also been key appointments in R&D and a high-profile addition to its boardroom, again with an R&D angle.

This newest position comes with a broad challenge to overhaul how technology is used moving forward.

Emma Walmsley, CEO of GSK, remained relatively tight-lipped regarding the appointment but commented: “The impact of technology on the healthcare industry is accelerating and requires us to rethink our approach. As a member of the Executive Team, Karenann will have the scope to think radically about how we can exploit the latest opportunities and ultimately improve our business performance.”

Quite how Terrel will achieve this latter aim has not been revealed but the recognition that the healthcare industry cannot remain outside the digital revolution is a sensible move – early innovators now will likely profit in the future.

Terrel is adequately placed, in terms of experience, to achieve this, coming with four years of experience in healthcare after working at Baxter as Chief Information Officer. More widely, she also worked for Chrysler and held a six year position at Walmart, with the title of Chief Information Officer. She will begin her new role in September.